Switch theme
Sign up to access all valuation multiples
Easywell Biomedicals Inc is engaged in drug development, manufacturing, and sales of active pharmaceutical ingredients and over-the-counter drug products The company's segment include the Drug development segment and Other segments.
1998
14
Last FY Revenue $18.0M
Last FY EBITDA $0.4M
$233M
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
In the most recent fiscal year, Easywell Biomedicals achieved revenue of $18.0M and an EBITDA of $0.4M.
Easywell Biomedicals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Easywell Biomedicals valuation multiples based on analyst estimates| NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|
| Revenue | XXX | $18.0M | XXX | XXX | XXX |
| Gross Profit | XXX | $10.0M | XXX | XXX | XXX |
| Gross Margin | XXX | 55% | XXX | XXX | XXX |
| EBITDA | XXX | $0.4M | XXX | XXX | XXX |
| EBITDA Margin | XXX | 2% | XXX | XXX | XXX |
| EBIT | XXX | -$2.3M | XXX | XXX | XXX |
| EBIT Margin | XXX | -13% | XXX | XXX | XXX |
| Net Profit | XXX | -$3.3M | XXX | XXX | XXX |
| Net Margin | XXX | -18% | XXX | XXX | XXX |
| Net Debt | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Easywell Biomedicals's stock price is TWD 56 (or $2).
Easywell Biomedicals has current market cap of TWD 6.9B (or $229M), and EV of TWD 7.0B (or $233M).
See Easywell Biomedicals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $233M | $229M | XXX | XXX | XXX | XXX | n/a |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Easywell Biomedicals has market cap of $229M and EV of $233M.
Easywell Biomedicals's trades at 12.9x EV/Revenue multiple, and 547.3x EV/EBITDA.
Equity research analysts estimate Easywell Biomedicals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Easywell Biomedicals's P/E ratio is not available.
See valuation multiples for Easywell Biomedicals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $229M | XXX | $229M | XXX | XXX | XXX |
| EV (current) | $233M | XXX | $233M | XXX | XXX | XXX |
| EV/Revenue | n/a | XXX | 12.9x | XXX | XXX | XXX |
| EV/EBITDA | n/a | XXX | 547.3x | XXX | XXX | XXX |
| EV/EBIT | n/a | XXX | -100.0x | XXX | XXX | XXX |
| EV/Gross Profit | n/a | XXX | n/a | XXX | XXX | XXX |
| P/E | n/a | XXX | -70.5x | XXX | XXX | XXX |
| EV/FCF | n/a | XXX | -40.6x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialEasywell Biomedicals's revenue per employee in the last FY averaged $1.3M, while opex per employee averaged $0.9M for the same period.
Easywell Biomedicals's rule of 40 is unknown (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Easywell Biomedicals's rule of X is unknown (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Easywell Biomedicals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| EBITDA Margin | n/a | XXX | 2% | XXX | XXX | XXX |
| EBITDA Growth | n/a | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | n/a | XXX | n/a | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | n/a | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.3M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.9M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | 7% | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 51% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 68% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Easywell Biomedicals acquired XXX companies to date.
Last acquisition by Easywell Biomedicals was XXXXXXXX, XXXXX XXXXX XXXXXX . Easywell Biomedicals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Easywell Biomedicals founded? | Easywell Biomedicals was founded in 1998. |
| Where is Easywell Biomedicals headquartered? | Easywell Biomedicals is headquartered in Taiwan. |
| How many employees does Easywell Biomedicals have? | As of today, Easywell Biomedicals has 14 employees. |
| Is Easywell Biomedicals publicy listed? | Yes, Easywell Biomedicals is a public company listed on ROCO. |
| What is the stock symbol of Easywell Biomedicals? | Easywell Biomedicals trades under 1799 ticker. |
| When did Easywell Biomedicals go public? | Easywell Biomedicals went public in 2008. |
| Who are competitors of Easywell Biomedicals? | Similar companies to Easywell Biomedicals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Easywell Biomedicals? | Easywell Biomedicals's current market cap is $229M |
| Is Easywell Biomedicals profitable? | Yes, Easywell Biomedicals is EBITDA-positive (as of the last 12 months). |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
